Display options
Cite
Basile J. Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals. Integr Blood Press Control. 2010;3:91-104doi: 10.2147/ibpc.s9691.
Basile, J. (2010). Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals. Integrated blood pressure control, 391-104. https://doi.org/10.2147/ibpc.s9691
Basile, Jan. "Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals." Integrated blood pressure control vol. 3 (2010): 91-104. doi: https://doi.org/10.2147/ibpc.s9691
Basile J. Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals. Integr Blood Press Control. 2010;3:91-104. doi: 10.2147/ibpc.s9691. Epub 2010 Jun 21. PMID: 21949625; PMCID: PMC3172072.
Copy Download .nbib Format: NLM
Share it on

Integr Blood Press Control. 2010;3:91-104. doi: 10.2147/ibpc.s9691. Epub 2010 Jun 21.

Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals.

Integrated blood pressure control

Jan Basile

Affiliations

  1. Professor of Medicine, Medical University of South Carolina, Charleston, SC, USA.

PMID: 21949625 PMCID: PMC3172072 DOI: 10.2147/ibpc.s9691

Abstract

Hypertension remains a significant health burden in the United States, with almost one in three adults affected, and is an independent risk factor for cardiovascular and renal disease. The goal of antihypertensive treatment is to reduce cardiovascular and renal morbidity and mortality by reducing blood pressure (BP). Guidelines recommend a target BP of <140/90 mmHg, with a more stringent goal of <130/80 mmHg for patients with diabetes and chronic renal disease. However, BP goal attainment rates remain low and most patients require therapy with two or more antihypertensive agents. Combination antihypertensive therapy usually employs agents from different classes, thus benefitting from complementary mechanisms of action to achieve greater BP control with fewer side effects. Patient adherence to therapy is enhanced by formulating treatments as fixed-dose (single-pill) combinations. One example is the combination of amlodipine, a dihydropyridine calcium channel blocker (CCB), with olmesartan medoxomil, an angiotensin receptor blocker (ARB). Here, the rationale for the use of CCB/ARB combination therapy is discussed, as well as the pharmacology and tolerability of the amlodipine/olmesartan medoxomil combination and its efficacy in terms of achieving BP goal in patients with hypertension. Advantages of its use from the patient's perspective are also discussed.

Keywords: amlodipine; angiotensin receptor blockers; calcium channel blockers; fixed-dose combination therapy; hypertension; olmesartan medoxomil

References

  1. Clin Ther. 2008 Apr;30(4):587-604 - PubMed
  2. J Clin Hypertens (Greenwich). 2009 Sep;11(9):475-82 - PubMed
  3. J Clin Hypertens (Greenwich). 2008 Nov;10(11):850-5 - PubMed
  4. Clin Pharmacokinet. 1992 Jan;22(1):22-31 - PubMed
  5. J Cardiovasc Pharmacol. 2005 Nov;46(5):585-93 - PubMed
  6. Am J Cardiovasc Drugs. 2008;8(1):45-50 - PubMed
  7. Vasc Health Risk Manag. 2008;4(3):653-64 - PubMed
  8. Diabetes Care. 1997 Oct;20(10):1512-7 - PubMed
  9. J Clin Pharmacol. 2008 Nov;48(11):1309-22 - PubMed
  10. Can J Cardiol. 1997 Oct;13(10):914-20 - PubMed
  11. BMJ. 2003 Jun 28;326(7404):1427 - PubMed
  12. Hypertension. 2007 Jan;49(1):69-75 - PubMed
  13. Lancet. 2005 Jan 15-21;365(9455):217-23 - PubMed
  14. J Clin Pharmacol. 2001 May;41(5):515-27 - PubMed
  15. JAMA. 2004 Nov 10;292(18):2217-25 - PubMed
  16. J Hypertens. 2007 Jun;25(6):1105-87 - PubMed
  17. J Hum Hypertens. 2010 Nov;24(11):730-8 - PubMed
  18. Lancet. 2002 Mar 23;359(9311):995-1003 - PubMed
  19. JAMA. 2003 Jul 9;290(2):199-206 - PubMed
  20. J Cardiovasc Pharmacol. 2009 Nov;54(5):427-36 - PubMed
  21. Am J Hypertens. 2008 May;21(5):509-13 - PubMed
  22. J Hypertens. 2004 Jun;22(6):1113-8 - PubMed
  23. J Clin Hypertens (Greenwich). 2009 Jul;11(7):358-68 - PubMed
  24. Hypertension. 2009 Jul;54(1):32-9 - PubMed
  25. J Hypertens. 2009 Jun;27(6):1136-51 - PubMed
  26. J Clin Hypertens (Greenwich). 2003 Nov-Dec;5(6 Suppl 4):17-25 - PubMed
  27. J Clin Hypertens (Greenwich). 2008 Jan;10(1):43-50 - PubMed
  28. Aust Fam Physician. 1997 Jul;26(7):841-5, 847-8 - PubMed
  29. J Hypertens. 2009 Nov;27(11):2121-58 - PubMed
  30. Am J Health Syst Pharm. 2008 Feb 1;65(3):209-18 - PubMed
  31. Clin Drug Investig. 2009;29(6):381-91 - PubMed
  32. Drugs. 1994 Jul;48(1):16-24 - PubMed
  33. Lancet. 2005 Sep 10-16;366(9489):895-906 - PubMed
  34. Clin Drug Investig. 2009;29(1):11-25 - PubMed
  35. Hypertension. 2000 Jan;35(1 Pt 2):155-63 - PubMed
  36. Clin Drug Investig. 2009;29(6):419-25 - PubMed
  37. JAMA. 2003 May 21;289(19):2560-72 - PubMed
  38. Clin Drug Investig. 2009;29(7):427-439 - PubMed
  39. Circulation. 2009 Jan 27;119(3):e21-181 - PubMed
  40. Postgrad Med. 2009 Mar;121(2):40-8 - PubMed
  41. Fundam Clin Pharmacol. 2009 Dec;23(6):767-74 - PubMed
  42. N Engl J Med. 2008 Apr 10;358(15):1547-59 - PubMed
  43. Congest Heart Fail. 2003 Nov-Dec;9(6):324-32 - PubMed
  44. Circulation. 2007 May 29;115(21):2761-88 - PubMed
  45. Circ J. 2008 May;72(5):764-9 - PubMed
  46. Int J Clin Pharmacol Res. 2005;25(1):41-6 - PubMed
  47. Lancet. 2008 May 3;371(9623):1513-8 - PubMed
  48. Hypertens Res. 2008 Jul;31(7):1373-83 - PubMed
  49. Postgrad Med. 2009 Mar;121(2):25-39 - PubMed
  50. Lancet. 2003 Nov 8;362(9395):1527-35 - PubMed
  51. N Engl J Med. 2008 Dec 4;359(23):2417-28 - PubMed

Publication Types